利干公司以7.39亿美元收购XOMA版权. Ligand to acquire XOMA Royalty for $739 million.

利根制药公司正在以约7.39亿美元的价格收购XOMA版权. Ligand Pharmaceuticals is acquiring XOMA Royalty for approximately $739 million. 这笔预计将于2026年完成的交易,增加了利并为Ligand投资组合添加120多个生物制药资产. The deal, expected to close in 2026, is accretive to earnings and adds over 120 biopharma assets to Ligand's portfolio. 利格兰在公告后提高了其2026年财政预期,两家公司的股票在市场前交易中上. Following the announcement, Ligand raised its fiscal 2026 guidance and both company shares rose in pre-market trading.